The number of years the cervical cancer vaccine lasts is not conclusive and varies from person to person. Current studies using the 9-valent cervical cancer vaccine as an example have found that the immunogenicity of the vaccine lasts approximately 6.4 years or more after the full course of vaccination. The cervical cancer vaccine, also called the human papillomavirus (HPV) vaccine, prevents infection of the body by high-risk subtypes of HPV viruses. The so-called high-risk HPVs are subtypes of HPVs that are clearly known to cause cervical cancer, and these viruses can also cause anal cancer, warts, and other diseases. Of the many clinical studies of cervical cancer vaccines, the 9-valent has been studied more frequently. According to research reports, after the standardized vaccination of the third dose of cervical cancer vaccine, the immunogenicity of the vaccine can last for 1 month, the immunological persistence can be maintained for 60 months, and the long-term protective effect can last for 6.4 years. However, the duration and efficacy of the cervical cancer vaccine varies from person to person and may not protect people who are already infected with the HPV subtypes contained in the vaccine. Since a woman’s risk of exposure to HPV increases as she ages, the earlier a woman receives the cervical cancer vaccine, the better. The specifics will depend on the population for which the different cervical cancer vaccines are indicated.